| Symbol | ARWR |
|---|---|
| Name | ARROWHEAD PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 177 E. COLORADO BLVD,SUITE 700, PASADENA, California, 91105, United States |
| Telephone | +1 626 - 304-3400 |
| Fax | — |
| — | |
| Website | https://www.arrowheadpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease. Additional info from NASDAQ: |
Apel Daniel Joseph 🔴 sold 13.1K shares of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) at $71.92 Transaction Date: Apr 22, 2026 | Filing ID: 000039
Read moreHamilton James C 🔴 sold 10.0K shares of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) at $75.00 Transaction Date: Apr 23, 2026 | Filing ID: 000007
Read moreArrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
Read more📋 James Hamilton (Officer) plans to sell 10K shares of Arrowhead Pharmaceuticals Inc. (at $75.00 each, total $750K) Filed: Apr 23, 2026 | ID: 026884
Read more📋 Daniel Apel (Officer) plans to sell 13K shares of Arrowhead Pharmaceuticals Inc. (at $71.34 each, total $934K) Filed: Apr 22, 2026 | ID: 026634
Read moreArrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
Read moreNew Form SCHEDULE 13G/A - ARROWHEAD PHARMACEUTICALS, INC. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000629 <b>Size:</b> 7 KB
Read moreHamilton James C 🔴 sold 10.0K shares of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) at $64.19 Transaction Date: Mar 05, 2026 | Filing ID: 000006
Read more📋 James Hamilton (Officer) plans to sell 10K shares of Arrowhead Pharmaceuticals (at $64.19 each, total $642K) Filed: Mar 05, 2026 | ID: 015264
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07221344 | Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Di… | Phase1 | Alzheimer Disease | Recruiting | 2025-11-18 | 2027-06-01 | ClinicalTrials.gov |
| NCT07037771 | A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous F… | Phase3 | Homozygous Familial Hypercholesterolemia | Recruiting | 2025-06-17 | 2027-08-20 | ClinicalTrials.gov |
| NCT06700538 | A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Typ… | Phase1 | Obesity | Recruiting | 2024-12-04 | 2028-01-17 | ClinicalTrials.gov |
| NCT06347133 | Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia | Phase3 | Hypertriglyceridemia | Active_Not_Recruiting | 2024-05-21 | 2026-09-01 | ClinicalTrials.gov |
| NCT06138743 | Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy | Phase1 | Myotonic Dystrophy 1 | Recruiting | 2024-03-04 | 2026-12-01 | ClinicalTrials.gov |
| NCT05217667 | Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia… | Phase2 | Homozygous Familial Hypercholesterolemia | Active_Not_Recruiting | 2022-04-22 | 2025-11-01 | ClinicalTrials.gov |
| NCT04202354 | Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohe… | Phase1 | Non-alcoholic Steatohepatitis | Completed | 2020-03-03 | 2021-09-03 | ClinicalTrials.gov |
| NCT03365947 | Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus… | Phase1 | Hepatitis B | Completed | 2018-03-27 | 2020-04-23 | ClinicalTrials.gov |
| NCT02604199 | A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) … | Phase2 | Hepatitis B | Terminated | 2015-09-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02535416 | A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers | Phase1 | Healthy | Completed | 2015-09-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02299414 | Chronic Hypertension and Pregnancy (CHAP) Project | Phase4 | Hypertension | Completed | 2015-06-01 | 2022-12-16 | ClinicalTrials.gov |
| NCT02363946 | A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Anti… | Phase1 | Alpha-1 Antitrypsin Deficiency | Terminated | 2015-02-01 | 2016-11-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| ARO-INHBE | Other | Phase PHASE1 | Obesity | RECRUITING | NCT06700538 |
| Statins | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT03936361 |
| Statins | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT03936361 |
| Statins | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT03936361 |
| Statins | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT03936361 |
| Statins | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT03936361 |
| Statins | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT03936361 |
| Statins | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT03936361 |
| Statins | Other | Phase PHASE3 | Intracerebral Hemorrhage | RECRUITING | NCT03936361 |